Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (141 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-11-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: transplantdonortransplantationstudy issubjects
  Phrases that lowered it: efficacypatientsevaluate theto evaluatehepatic
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 51.9% (raises risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Phase: 1 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 98.0% (raises risk) · Drug's FDA history
• Maximum age: 70 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation NCT02544113 · started 2015 · scored riskier than 93% of active trials completed
• Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation NCT03031470 · started 2015 · scored riskier than 86% of active trials terminated
• A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients NCT00619398 · started 2008 · scored riskier than 34% of active trials completed
• Terlipressin Administration in Patients Undergoing Major Liver Resection NCT01921985 · started 2013 · scored riskier than 75% of active trials terminated
• Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients NCT02166177 · started 2014 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.